Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Many people with Parkinson's disease (PwPD) lack optimal care due to limited access to neurologists and a reliance on subjective rating scales for treatment decisions. The Ceraxis Insight platform was designed to provide quantitative measures of the cardinal motor symptoms of Parkinson's disease (PD) through self-administered assessments performed using a tablet paired with a sensor-embedded stylus. The aim of this study was to assess the validity of the Ceraxis Insight outcome metrics against clinical gold-standard measures of PD motor symptoms. Nineteen PwPD completed a clinical examination and the nine Ceraxis Insight assessment modules. Quantitative performance metrics were calculated from the platform's IMU, force transducer, and touchscreen inputs. Mixed-effect models and correlation analyses determined that multiple quantitative metrics from the Ceraxis Insight modules significantly predicted (p 0.70) with the MDS-UPDRS III total score, bradykinesia, tremor, rigidity, and postural instability and gait difficulty sub-scores. Logistic regression models determined that multiple Ceraxis Insight metrics discriminated between ON- and OFF-deep brain stimulation (DBS) conditions, with Area Under the Receiver Operating Characteristic Curve (AUC) values exceeding 0.70. The Ceraxis Insight platform provides a validated, objective assessment of PD motor symptoms that may be performed within clinical or remote settings for data-driven evaluation and treatment.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.